• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SVRA

SVRA

Savara Inc.

NASDAQHealthcareBiotechnologyUS

USD5.25

+0.00 (+0.00%)

Rating:C-

Company Profile

CEO

Matthew Pauls

IPO Date

2017-04-28

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.29

Prev. Close

$5.25

Day Low

$5.12

Day High

$5.41

52W Low

$1.98

52W High

$7.00

Market Cap

$1.08B

Volume

1.79M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

40.1%

Avg Negative

10.8%

Avg Neutral

49.3%

News Feed

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Zacks Investment Research·7/1/2021·↑ positive

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Business Wire·6/30/2021·↑ positive

Savara: They Failed Once, But They Are Trying Again

Seeking Alpha·6/7/2021·↑ positive

Savara to Present at the Jefferies Virtual Healthcare Conference

Business Wire·5/26/2021·↑ positive

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

24/7 Wall Street·5/22/2021·↓ negative

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

Business Wire·5/17/2021·↑ positive

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire·5/14/2021·↑ positive

Savara Stock Rallies: Technical Analysis Levels

Benzinga·3/16/2021·↑ positive

SVRA Stock Price Increases Over 30% Pre-Market: Why It Happened

Pulse2·3/16/2021·↑ positive

Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' Option

Business Wire·3/15/2021·↑ positive